Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT00461773
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Letrozole — DRUG
    Letrozole 2.5 mg po qd
  • Bevacizumab — DRUG
    bevacizumab 10 mg/kg IV

Study Details

The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal patients with hormone sensitive breast cancer.

Key Dates

First listed
Apr 18, 2007
Start date
Mar 31, 2007
Status verified
Feb 2021
Primary completion
May 31, 2010
Completion
May 31, 2010

Study Design

Enrollment
5 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: bevacizumab
    brief exposure bevacizumab
  • Active Comparator: bevacizumab and letrozole
    brief exposure bevacizumab and letrozole

Primary Outcome Measure

Number of Patients With Objective Tumor Response [ Time Frame: Up to 18 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale University, Yale Cancer CenterNew HavenConnecticut06520-

Find similar trials in New Haven, CT

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Yale University, Yale Cancer Center· New Haven, CT

Related Studies